Bayer (BAYN) PT Set at €120.00 by Deutsche Bank

Deutsche Bank set a €120.00 ($148.15) price target on Bayer (FRA:BAYN) in a research report released on Thursday. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the topic of several other reports. Citigroup reissued a buy rating on shares of Bayer in a research report on Friday, February 16th. Nord/LB restated a neutral rating on shares of Bayer in a research note on Wednesday, December 27th. DZ Bank restated a buy rating on shares of Bayer in a research note on Monday, December 11th. UBS restated a buy rating on shares of Bayer in a research note on Monday, January 15th. Finally, Warburg Research set a €121.00 ($149.38) target price on Bayer and gave the company a neutral rating in a research note on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. Bayer currently has a consensus rating of Buy and an average target price of €118.23 ($145.96).

How to Become a New Pot Stock Millionaire

Bayer stock opened at €90.86 ($112.17) on Thursday. Bayer has a 52-week low of €91.58 ($113.06) and a 52-week high of €123.82 ($152.86). The company has a market capitalization of $78,800.00 and a PE ratio of 24.42.

COPYRIGHT VIOLATION NOTICE: “Bayer (BAYN) PT Set at €120.00 by Deutsche Bank” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3301016/bayer-bayn-pt-set-at-120-00-by-deutsche-bank.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Entegra Financial  PT Set at $33.00 by Sandler O’Neill
Entegra Financial PT Set at $33.00 by Sandler O’Neill
Extra Space Storage  Set to Announce Earnings on Tuesday
Extra Space Storage Set to Announce Earnings on Tuesday
MGM Growth Properties  Scheduled to Post Quarterly Earnings on Thursday
MGM Growth Properties Scheduled to Post Quarterly Earnings on Thursday
-$0.22 Earnings Per Share Expected for Fate Therapeutics  This Quarter
-$0.22 Earnings Per Share Expected for Fate Therapeutics This Quarter
Akorn  Receives “Hold” Rating from Craig Hallum
Akorn Receives “Hold” Rating from Craig Hallum
Bilibili  Coverage Initiated at Morgan Stanley
Bilibili Coverage Initiated at Morgan Stanley


© 2006-2018 Ticker Report. Google+.